Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Hagop M. Kantarjian, Anjali S. Advani, Matthias Stelljes et al.|Cancer|2019

Cited by 327